StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Insight Molecular Diagnostics's ebitda for the twelve months ending Jun 30, 2026 was -$47.86M. For fiscal 2025 it was -$48.93M. The highest annual figure on record is -$16.47M in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.93M–
FY2024Dec 31, 2024-$59.48M–
FY2023Dec 31, 2023-$23.46M–
FY2022Dec 31, 2022-$16.47M–
FY2021Dec 31, 2021-$52.93M–
FY2020Dec 31, 2020-$29.40M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.74M–
Q1 FY2026Mar 31, 2026-$3.78M–
Q4 FY2025Dec 31, 2025-$22.87M–
Q3 FY2025Sep 30, 2025-$10.46M–
Q2 FY2025Jun 30, 2025-$9.28M–
Q1 FY2025Mar 31, 2025-$6.31M–
Q4 FY2024Dec 31, 2024-$33.06M–
Q3 FY2024Sep 30, 2024-$13.18M–
Q2 FY2024Jun 30, 2024-$4.31M–
Q1 FY2024Mar 31, 2024-$8.93M-241.8%
Q4 FY2023Dec 31, 2023-$15.79M–
Q3 FY2023Sep 30, 2023-$6.11M–
Q2 FY2023Jun 30, 2023-$7.86M–
Q1 FY2023Mar 31, 2023$6.30M–
Q4 FY2022Dec 31, 2022-$11.22M–
Q3 FY2022Sep 30, 2022-$1.32M–
Q2 FY2022Jun 30, 2022-$1.24M–
Q1 FY2022Mar 31, 2022-$2.73M–
Q4 FY2021Dec 31, 2021-$35.46M–
Q3 FY2021Sep 30, 2021-$13.35M–
Q2 FY2021Jun 30, 2021-$13.36M–
Q1 FY2021Mar 31, 2021-$11.24M–
Q1 FY2020Mar 31, 2020-$8.37M–

More Insight Molecular Diagnostics figures

See a number that looks wrong?